Member Info for Vertizea-Sun

Avacta management has seen early Phase1B data and the information will be available under NDA rules, in a Data Room.

I've no idea if the above is true but as everybody on the board is making willy-nilly assertions I thought I'd join in.

Both are irrelevant with less than half of one per cent of outstanding shares traded each day. Any rise will be sold into by dime-a-day-traders. We'll just have to be patient until the first RNS with a meaningful £$ sign in it. It will happen.....150 patients successfully treated with pre|CISION guarantees it.

"The most obvious conclusion is that it is an error on a poorly proof read slide and should be 385/260 as above."

Are you *******serious? At least a dozen scientists and senior management perused that document but the Mighty Touk knows better.

Seriously.... you meant it as a joke didn't you?

Typical B*****. Firstly....If the link isn't working then you can't have read the 13 mentions Avacta gets.

Secondly....the AVA6000 trial didn't begin with Phase1B.Imbecile.

You stay in denial. I'm loving it.

"We’ll see how this plays out soon enough."

And this means not another four years but closer to four months. Nothing lasts for ever....even rubbish news so anyone thinking we'll have to wait for published Phase1B data before BP makes a move is going to make one of life's great mistakes.

It's easy to forget just how much cash BP sits on....Novartis for example has $11billion on its NYE published accounts, and Lord knows how much in homeland Switzerland. Eating Avacta will be a light snack.

The man claiming AVA6000 is EXCEPTIONAL is the US oncologist/surgeon actually using it.....at MSK, New York.

https://www.alainelkanninterviews.com/virgilio-sacchini-4/......this interview from December

"Virgilio Sacchini, is the Pre|CISION® platform of Avacta, a British life sciences firm, a good example of how new technology can expand the reach of highly potent cancer therapies?

Avacta is an incredible application of biomedical engineering. For a treatment to have most efficacy we need to have a very powerful medication, and to be sure that the medication targets the right cells. If you have a very powerful medication going everywhere in the body, of course it can go to the cancer cells, but it may also go to other healthy cells, creating toxicity. The new concept is to target only cancer cells.

Can Avacta limit the side effects of chemotherapy by going straight to the point?

Yes, it goes straight to the environment of the cancer cells."

Https://x.com/MylesMcNulty/status/1905542514490441784

3 years, 8 months of clinical data (and btw, I don't think it's discussed enough that there has been at least one patient on an AVA6000 treatment plan, for every single day throughout that entire period. That's an immense amount of data collected now). The MoA of the delivery platform has been proven beyond doubt.

I do hope that's the last one for the day.

Indeed she does!

• Bone marrow toxicities are dramatically reduced when comparing AVA6000 versus conventional dose doxorubicin

• AVA6000 has no severe cardiac toxicity despite doses approaching 4x the MTD of conventional doxorubicin (75 mg/m2)

• Alopecia is generally limited to hair thinning (grade 1) and not complete hair loss

• There are no reports of ADC-linked toxicities associated with non- specific release of the payload with AVA6000 (including no pneumonitis, no ocular toxicity and no liver toxicity)

Perhaps the new info was due for release at AACR?

The final slide is new info.....to me anyway and is good stuff:

FAP-EXd (AVA6103): First program developed by Avacta with a novel, sustained released mechanism of action based on the FAP- cleavable peptide. The Program IP is owned by Avacta, based on the foundational patents with Program patent expiry in 2045

Yes cj62....I take your point about the timing of a partnership for TNBC......later this year.

Unfortunately all we've got to go on is:

"Intention to explore licensing and partnering opportunities. Avacta is seeking a partnership to develop AVA6000"

Nursesteve......all true but Avacta's problem is running out of financial road before Phase 1B data is available and how to pay for Phase2. The company owes us a commercial update.

I sort of agree with IFA but it would have e looked odd to stay away. But it begs the question - again - what has Simon Bennett done in 15 months of employment?

If you don't know who Charlie Munger was then you should stick to a savings account:

"The wise ones bet heavily when the world offers them that opportunity. They bet big when they have the odds. And the rest of the time, they don’t. It’s just that simple."

no.....it follows the first law of coding - **** in....**** out.

Does it matter? We know it works.

COLDWATER......absolutely CC is determined to lead for the foreseeable future and NASDAQ will be the vehicle. I've lost track of the heads-up.

Avacta signed into a Chinese drug production company (in a manner of speaking) nearly three years ago in April 22:

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that AffyXell Therapeutics ("AffyXell"), a joint venture between Avacta and Daewoong Pharmaceutical ("Daewoong"), has entered into a collaboration agreement with Biocytogen, a Chinese company specializing in developing new biological drugs, and the Korea Non-Clinical Technology Solution Center ("KNTSC").